{"nctId":"NCT01115582","briefTitle":"Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis","startDateStruct":{"date":"2010-04"},"conditions":["Inborn Errors of Bile Acid Synthesis"],"count":16,"armGroups":[{"label":"Cholic Acid Capsule","type":"EXPERIMENTAL","interventionNames":["Drug: Cholic acid"]}],"interventions":[{"name":"Cholic acid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* must have stable transaminase levels within 2 times the upper limits of the normal range.\n* must have a diagnosis of an inborn error of bile acid synthesis.\n* must have signed the written informed consent/assent document before study start.\n* must be currently receiving currently used cholic acid therapy under IND 45,470.\n* must be willing and able to comply with all study assessments and procedures.\n* must be able to make two visits (Visit 1 and Visit 2) to the study site.\n\nExclusion Criteria:\n\n* is not currently receiving cholic acid therapy for inborn errors of bile acid synthesis under IND 45,470.\n* is unable or unwilling to comply with study requirements.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serum Transaminases","description":"Concentration of serum alanine transaminase (ALT) and aspartate transaminase (AST)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"21.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":"24.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":"27.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","spread":"39.0"}]}]}]},{"type":"PRIMARY","title":"Serum and Urine Bile Acids","description":"Concentration of bile acids in serum (S) and urine (U). (abbreviations: chol.=cholenoic; monohydro=monohydroxy; dihydro=monohydro)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.37","spread":"35.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.762","spread":"3.955"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.11","spread":"42.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.011","spread":"2.995"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159.85","spread":"474.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.958","spread":"29.341"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105.43","spread":"337.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.421","spread":"7.633"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.055","spread":"0.078"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.140","spread":"0.184"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.490","spread":"0.679"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.028"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"291.77","spread":"889.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.148","spread":"43.582"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.705","spread":"0.601"}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Total number of patients with any adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Pressure","description":"Systolic blood pressure (SBP) and diastolic blood pressure (DBP)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106.9","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.6","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Physical Examination","description":"Total number of patients with abnormal findings from general physical examination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Bilirubin","description":"Concentration of total bilirubin in serum","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.28"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":16},"commonTop":["Decreased/low 250H/Vit D","Decreased Vitamin A","Nosebleed","Diarrhoea","Reflux"]}}}